CORAL HEARD: Open Payments
NPI 1023378783 · HOT SPRINGS, AR. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$560 in 39 payments from 10 companies in 2025. Trend: 2023 $676 · 2024 $392 · 2025 $560
Food & beverage: $560
| Company | Payments | Amount |
|---|---|---|
| Dexcom, Inc. | 12 | $144 |
| Lilly USA, LLC | 13 | $135 |
| AstraZeneca Pharmaceuticals LP | 5 | $88 |
| ABBVIE INC. | 2 | $45 |
| ABIOMED | 1 | $39 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 1 | $25 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $23 |
| Antares Pharma, Inc. | 1 | $16 |
| Merck Sharp & Dohme LLC | 1 | $14 |
Products named: Dexcom G6 Transmitter, JARDIANCE, MOUNJARO, FARXIGA, BREZTRI, CAPLYTA, UBRELVY, REXULTI.
Industry payments across AR — which companies pay providers there.
